Saturday, 14 November 2020 from 14:00 to 16:00 CET

from 14:00 to 16:00 CET

from 16:00 to 18:00 MSK

from 21:00 to 23:00 CST


High blood pressure is the most important cardiovascular risk factor and the leading cause of death worldwide. The contribution of hypertension to morbidity and mortality has remained stable in the last decade, despite considerable advances in the treatment of the disease. This is likely due to a number of factors, including a lack of treatment personalization, where medication is matched to the patient by considering the underlying metabolic pathways that have contributed to the hypertension, as well as a lack of adherence by patients to their prescribed medication.
One important aspect is the activation of the sympathetic nervous system. Despite its fundamental role in the pathogenesis of cardiovascular disease, only recent 2018 European Society of Hypertension / European Society of Cardiology Hypertension Guidelines have included elevated heart rate, the easiest way to assess sympathetic nervous system activity, among the factors influencing cardiovascular risk in patients with hypertension.
Beta-blockers are effective drugs for reducing resting heart rate and have been shown to improve blood pressure control, leading to a reduction in cardiovascular mortality in several randomized, placebo-controlled trials. A better understanding of the rationale behind beta-blocker treatment, the potential benefits and side-effects, as well as the differences between different beta-blockers is, therefore, crucial in identifying t+he hypertensive patients who could benefit the most from this treatment or combination treatment with beta-blockers.
Finally, the adverse effects of hypertension and other risk factors on morbidity and mortality has been recently highlighted by the dramatic COVID-19 pandemic. There is evidence that patients with hypertension, particularly males, are at increased risk for a poor outcome or death from COVID-19. Consideration of the available data are important so that the risks to patients with hypertension can be considered, best practice to treat those who are infected can be shared and policies can be adopted to support those who are not infected, but who need help and support to manage their hypertension at a time when face-to-face meetings with healthcare professionals are limited.

Learning objectives

By attending this live webinar, participants will be able to:

  • Acquire information about the strong relationship between COVID-19 and cardiovascular disease, with particular emphasis on whether COVID-19 itself is a promoter of cardiac damage or whether pre-existing cardiovascular risk factors or disease worsen the prognosis in COVID-19 patients.
  • Identify the role of increased sympathetic nervous system activity in the pathogenesis of hypertension and hypertension-related disease; in addition, the choice of appropriate treatment to reduce increased sympathetic nervous system activity will be discussed.
  • Learn how to optimize the use of beta-blockers in patients with different cardiovascular complications, including coronary artery disease and heart failure.

Target audience

This activity is designed for Cardiologists, General Practitioners, Internists and those treating patients with cardiovascular disorders.


Giuseppe Mancia
Professor Emeritus
University of Milano-Bicocca
Milan, Italy

Harry A.J. Struijker-Boudier
Department of Pharmacology and Toxicology
Cardiovascular Research Institute Maastricht
Maastricht University, The Netherlands



Stefano Taddei
Director of the Hypertension Unit
Department of Clinical and Experimental Medicine
University of Pisa, Italy



Marijana Tadic
Honorary consultant
University Hospital
“Dr. Dragisa Misovic”
Belgrade, Serbia



Brian Tomlinson
Faculty of Medicine
Macau University of Science & Technology
Taipa, Macau, China



Scientific Program

14:00                Welcome and introduction – Taddei (Italy)

14:10     L1       The cardiovascular system in COVID-19: Primary target or secondary bystander? – Mancia (Italy)

14:30     L2      Targeting heart rate in the treatment of hypertension – H.A.J. Struijker-Boudier (The Netherlands)

14:50     L3      Best practice in the management of stable chronic angina – Tadic (Serbia)

15:10      L4      From hypertension to heart failure: Prevention strategies – Tomlinson (China)

15:30     P        Panel discussion

16.00                End of the live webinar


Faculty Disclosures

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter).
We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Giuseppe Mancia Declared receipt of honoraria or consultation fees from Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Menarini, Merck, Novartis, Recordati, Sanofi, Servier.
Harry A.J. Struijker-Boudier Declared no potential conflict of interest
Stefano Taddei Declared receipt of grants and contracts from Boehringer Ingelheim and Regione Toscana and participation in Servier and Pfizer speaker’s bureau
Marijana Tadic Declared no potential conflict of interest
Brian Tomlinson Declared no potential conflict of interest

This independent educational activity is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.


Copyright 2020 Scientific Seminars International Foundation